Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.

Abstract: Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Abstract: A non-invasive, wearable and portable medical device for evaluation and monitoring the heart condition for patients with congestive heart failure and a CHF management system is provided comprising a wearable textile-based device utilizing physiologic and biometric sensors, a Signal Acquisition Unit, and a monitoring system executing a suite of software algorithms to monitor and evaluate patients with CHF.

Abstract: A memory system includes a memory device including a plurality of memory blocks and a memory controller. The memory controller determines, when a read request for data stored in a first memory block among the plurality of memory blocks is received, whether a dummy read operation on the first memory block is to be performed, based on an erase count value of a second memory block which shares a block word line with the first memory block before a read operation on the first memory block is performed.

Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

Abstract: An example embodiment of the present disclosure relates to a nanofiber scaffold including polycaprolactone (poly(?-caprolactone; PCL), decellularized extracellular matrix (dECM) and usnic acid (UA), and a preparation method thereof. The nanofiber scaffold of an example embodiment of the present disclosure has a uniform nanofiber structure, good fluid absorption and retention, moderate release rate, high mechanical stability, thermal stability, and semi-crystalline structure, and exhibits excellent antibacterial efficacy against fungi/bacteria such as Candida albicans, and good compatibility with human-derived fibroblasts.

Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: A method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment is disclosed. The method includes steps of conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment. Also disclosed is a composition for improving the solubility of a physiologically active protein or peptide, which contains an immunoglobulin Fc fragment. The composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.

Abstract: Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Abstract: The present invention relates to polyethylene glycol derivatives and use thereof.

Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.

Abstract: There are provided a memory controller and a memory system having the same. The memory controller includes: a central processing unit configured to output a read command for checking an erase state of a selected storage region in response to a program request from a host, determine the number of dummy pages according to the erase state, and output a program command according to the number of dummy pages; and a memory interface configured to, when user data corresponding to the program request is output to the selected storage region, selectively generate dummy data corresponding to the number of dummy pages, and output the dummy data with the user data.

Abstract: A method for preparing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using an organic solvent is provided. A method for preparing a physiologically active polypeptide complex by linking the conjugate with a carrier is provided. The complex shows improved in vivo duration and stability of the physiologically active polypeptide. The method can prepare the conjugate at a lower production cost, and the resulting conjugate shows an extension of in vivo activity at a relatively high level and significantly increase in the blood half-life.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.

Abstract: A method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof is disclosed. The method includes site-specifically binding a carrier to a protein or peptide. A protein or peptide produced by the method and the uses thereof are disclosed. The conjugate of the physiologically active protein or peptide can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.

Abstract: The technology disclosed in this patent document can be implemented in embodiments to provide a memory controller configured to control a memory device and a method of operating the memory controller and the memory device. The memory controller may control a memory device including a plurality of pages, and may include a command analysis unit configured to generate command information indicating a type of read command for a page selected from among the plurality of pages, and an initialization time decision unit configured to decide on a channel initialization time for initializing channels of a plurality of memory cells included in the selected page based on the command information.